Wystepowanie w materiale klinicznym i lekowrazliwosc szczepow Stenotrophomonas maltophilia

• Autorzy: Hankiewicz-Ziolkowska K. , Mikucka A. , Gospodarek E.

Warianty tytułu

EN

Clinical strains isolation and antibiotic susceptibility of Stenotrophomonas maltophilia

• Języki publikacji: PL

Abstrakty

PL

Celem pracy była ocena częstości występowania i lekowrażliwości szczepów Stenotrophomonas maltophilia w materiale pobranym od chorych hospitalizowanych w Szpitalu Uniwersyteckim nr 1 im. dr. A. Jurasza w Bydgoszczy w okresie trzech lat. Najczęściej pałeczki 5. maltophilia izolowano od chorych Kliniki Anestezjologii i Intensywnej Terapii z Pododdziałem Kardioanestezjologii oraz Kliniki Chirurgii Dziecięcej. Najwięcej (95,7%) szczepów wykazywało wrażliwość na lewofloksacynę i trimetoprim/sulfametoksazol (71,2%).

EN

Stenotrophomonas maltophilia is an opportunistic Gram-negative bacillus which is becoming increasingly recognized as an important nosocomial pathogen especially in debilitated or immune suppressed patients. S. maltophilia is found in a wide variety of environments. It has been isolated from a number of water sources, soil, variety of plants and food sources. S. maltophilia can form biofilm on synthetic materials for temporary or permanent implantation, i.e. central venous catheters, urinary catheters and prosthetic heart valves. In hospital the organism has been isolated from wet environments such as antiseptic fluids containing Chlorhexidine, respiratory therapy equipment and air nebulizers. Little is known of the virulence factors of S. maltophilia. S. maltophilia is naturally resistant to many currently available broad-spectrum antimicrobial agents, including carbapenems. This study was carried out with the objective of evaluating clinical strains isolation and antibiotic susceptibility of S. maltophilia. A total of 80 clinical isolates of S. maltophilia were collected from individual patients, hospitalized at A. Jurasz University Hospital in Bydgoszcz, Poland. To identify S. maltophilia strains and receive biochemical profiles API 20 NE tests (bio Mérieux) ATB Expression computer system (bio Mérieux) with database V 2.4.7. were used. Antimicrobial agents susceptibility was evaluated for 19 different agents. For 18 out of 19 antimicrobial agent Etests (AB Biodisc) were used. For levofloxacine disc diffusion method was used. Most of analyzed strains were isolated from broncho-alveolar lavage (37,5%) from patients hospitalized in Intensive Care Unit (48,8%). 95,7% of isolated strains were susceptible to levofloxacine and 71,3% to trimethoprim/sulfametholxazole. 48 (60,0%) of S. maltophilia strains were identified as multi-drug resistant.

Słowa kluczowe

PL

material kliniczny; szczepy bakteryjne; wrazliwosc na leki; Stenotrophomonas maltophilia; pacjenci; nowotwory; antybiotyki karbapenemowe; opornosc na antybiotyki

• Wydawca: -
• Czasopismo: Medycyna Doświadczalna i Mikrobiologia
• Rocznik: 2010
• Tom: 62
• Numer: 2
• Opis fizyczny: s.127-134,rys.,tab.,bibliogr.

Twórcy

autor

Hankiewicz-Ziolkowska K.

• Collegium Medicum im.Ludwika Rydygiera w Bydgoszczy, Uniwersytet Mikolaja Kopernika w Toruniu, ul.M.Curie-Sklodowskiej 9, 85-094 Bydgoszcz

autor

Mikucka A.

autor

Gospodarek E.

Bibliografia

• 1. Ansari SR, Hachem R, Rolston K, Raad l i inni. Risk factors for infections with multidrug-resistant Stenotrophomonas maltophilia in patients with cancer. Cancer 2007; 109: 2615-22
• 2. BSAC standardized disc susceptibility testing method (version 6). J Antimicrob Chemother 2007; 60: 20-41
• 3. Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998; 11: 57-80
• 4. Gales AC, Jones RN, Forward KR i inni. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin Infect Dis 2001; 32: 104-13
• 5. Khardori N, Elting L, Wong E, Schable B, Bodey GP. Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with canccr. Rev Infect Dis 1990; 12: 997-1003
• 6. Micozzi A, Venditti M, Monaco M i inni. Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies. Clin Infect Dis 2000; 31: 705-11
• 7. Morrison AJ, Hoffmann KK, Wenzel RP. Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital. J Clin Microbiol 1986; 24: 52-5
• 8. Muder RR, Harris AP, Muller S i inni. Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clin Infect Dis 1996; 22: 508-12
• 9. Penzak SR, Abate BJ. Stenotrophomonas (Xanthomonas) maltophilia: a multidrug-resistant nosocomial pathogen. Pharmacotherapy 1997; 17: 293-301
• 10. Performance standards for antimicrobial susceptibility testing; Sixteenth Informational Supplement. 2006; CLSI M100-S16
• 11. Rekomendacje doboru testów do oznaczania wrażliwości bakterii na antybiotyki i chemioterapeutyki 2009. Krajowy Ośrodek Referencyjny ds. Lekowrażliwości Drobnoustrojów
• 12. Saino Y, Inoue M, Mitsuhashi S. Purification and properties of an inducible cephalosporinase from Pseudomonas maltophilia GN12873. Antimicrob Agents Chemother 1984; 25: 362-5
• 13. Sanyal SC, Mokaddas EM. The increase in carbapenem use and emergence of Stenotrophomonas maltophilia as an important nosocomial pathogen. J Chemother 1999; 11: 28-33